Stocks and InvestingStocks and Investing
Fri, April 8, 2022
Thu, April 7, 2022
Wed, April 6, 2022
Tue, April 5, 2022

Mohit Bansal Maintained (VRTX) at Buy with Increased Target to $300 on, Apr 5th, 2022


Published on 2024-10-27 20:18:01 - WOPRAI, Mohit Bansal
  Print publication without navigation


Mohit Bansal of Wells Fargo, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Buy with Increased Target from $270 to $300 on, Apr 5th, 2022.

Mohit has made no other calls on VRTX in the last 4 months.



There are 7 other peers that have a rating on VRTX. Out of the 7 peers that are also analyzing VRTX, 2 agree with Mohit's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Maintained at Hold and Held Target at $269 on, Thursday, March 31st, 2022
  • Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $222 on, Thursday, January 27th, 2022


These are the ratings of the 5 analyists that currently disagree with Mohit


  • Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $350 on, Monday, April 4th, 2022
  • Liisa Bayko of "Evercore ISI Group" Maintained at Buy with Increased Target to $278 on, Friday, April 1st, 2022
  • Brian Skorney of "Baird" Maintained at Buy and Held Target at $240 on, Wednesday, March 23rd, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $275 on, Thursday, January 27th, 2022
  • Evan Seigerman of "BMO Capital" Upgraded from Hold to Buy and Increased Target to $274 on, Thursday, January 20th, 2022